Publications by authors named "Steven Swerdlow"

The oncogenic Epstein-Barr virus (EBV) can drive tumorigenesis with disrupted host immunity, causing malignancies including post-transplant lymphoproliferative disorders (PTLDs). PTLD can also arise in the absence of EBV, but the biological differences underlying EBV(+) and EBV(-) B cell PTLD and the associated host-EBV-tumor interactions remain poorly understood. Here, we reveal the core differences between EBV(+) and EBV(-) PTLD, characterized by increased expression of genes related to immune processes or DNA interactions, respectively, and the augmented ability of EBV(+) PTLD B cells to modulate the tumor microenvironment through elaboration of monocyte-attracting cytokines/chemokines.

View Article and Find Full Text PDF

Post-transplant lymphoproliferative disorders (PTLDs) remain a feared complication of transplantation, with significant morbidity and mortality. The oncogenic Epstein-Barr virus (EBV) is a key pathogenic driver in 50%-80% of cases. Numerous prognostic indices, comprising multiple clinical, epidemiological and tumor characteristics, including EBV tumor positivity, do not consistently associate with worse patient survival, suggesting a potential role for EBV genome variants in determining outcome.

View Article and Find Full Text PDF
Article Synopsis
  • * Strong recommendations include reducing immunosuppression as an initial management step and using the anti-CD20 monoclonal antibody (rituximab), as well as chemotherapy in specific cases.
  • * There is a lack of large randomized phase III trials for treating PTLD in pediatrics, leading to reliance on clinical experience, and the report emphasizes the need for future research on this topic.
View Article and Find Full Text PDF

Most Pathology residents take the Anatomic Pathology and/or Clinical Pathology primary pathology certification examination(s) near the end of their final year of training (i.e., Spring), whereas some postpone the examination(s) to the Fall administration of that year or even later.

View Article and Find Full Text PDF

Whole-genome sequencing of longitudinal tumor pairs representing transformation of follicular lymphoma to high-grade B cell lymphoma with MYC and BCL2 rearrangements (double-hit lymphoma) identified coding and noncoding genomic alterations acquired during lymphoma progression. Many of these transformation-associated alterations recurrently and focally occur at topologically associating domain resident regulatory DNA elements, including H3K4me3 promoter marks located within H3K27ac super-enhancer clusters in B cell non-Hodgkin lymphoma. One region found to undergo recurrent alteration upon transformation overlaps a super-enhancer affecting the expression of the PAX5/ZCCHC7 gene pair.

View Article and Find Full Text PDF

Primary cutaneous B-cell lymphomas (PCBCLs) are lymphoproliferative disorders that appear on the skin without evidence of extracutaneous manifestations at the time of diagnosis. There is a lack of evidence-based guidelines for their clinical management due to the availability of very few large scale studies and controlled clinical trials. Here we present and discuss a series of major unmet clinical needs (UCNs) in the management of PCBCLs by a panel of 16 experts involved in research and clinical practice of PCBCL.

View Article and Find Full Text PDF
Article Synopsis
  • The t(14;19)(q32;q13) chromosomal rearrangement leads to the overexpression of the BCL3 gene through its juxtaposition with the immunoglobulin heavy chain (IGH) gene, affecting various lymphoid neoplasms.
  • An analysis of 13 lymphoid neoplasms with BCL3 rearrangement identified two distinct breakpoint clusters that result in different clinical outcomes: 5' breakpoints near an IGH enhancer causing overexpression of BCL3, and 3' breakpoints leading to no overexpression.
  • The study revealed that upstream BCL3-R tumors are related to atypical chronic lymphocytic leukemia while downstream BCL3-R tumors are linked to marginal zone lymphomas,
View Article and Find Full Text PDF
Article Synopsis
  • The International Pediatric Transplant Association held a conference to create guidelines for managing post-transplant lymphoproliferative disorders (PTLD) in children, focusing on how to use biomarkers like Epstein-Barr virus (EBV) levels for patient care.
  • The group recommends using "EBV DNAemia" for measuring EBV DNA in blood and advises caution when comparing results from different labs. They concluded both whole blood and plasma can be used for testing, depending on the clinical situation.
  • It is suggested that quantitative EBV DNAemia testing can help identify children at risk for PTLD, especially those who were EBV negative before their transplant, but overall routine surveillance is not recommended for
View Article and Find Full Text PDF

Mucosa-associated lymphoid tissue (MALT) lymphomas often express IgM and IRTA1 with only a minority demonstrating plasmacytic differentiation. However, like primary cutaneous marginal zone lymphoproliferative disorders (PCMZLPD), thyroid MALT lymphomas (T-MALT-L) frequently show plasmacytic differentiation and IgG positivity. Whether T-MALT-L share other features with PCMZLPD, including frequent IgG4 positivity and infrequent IRTA1 expression, and how IRTA1 staining compares to that in Hashimoto thyroiditis (HT) are unknown.

View Article and Find Full Text PDF

The International Pediatric Transplant Association (IPTA) Consensus Conference on Practice Guidelines for the Diagnosis, Prevention, and Management of Post-Transplant Lymphoproliferative Disorders after Solid Organ Transplantation in Children took place on March 12-13, 2019, and the work of conference members continued until the end of December 2021. The goal was to produce evidence-based consensus guidelines on the definitions, diagnosis, prevention, and management of PTLD and related disorders based on the critical review of the literature and consensus of experts. This report describes the goals, organization, and methodology of the consensus conference and follow-up activities.

View Article and Find Full Text PDF

We investigated the clinicopathologic features of 5 follicular lymphomas (FLs) that transformed (tFL) morphologically to diffuse large B-cell lymphomas (DLBCLs) and had a primary mediastinal large B-cell lymphoma (PMBL)-like gene expression profile (tFL-PMBLsig-pos). None of the tFL-PMBLsig-pos cases arose in the mediastinum, all cases tested had a germinal center B-cell phenotype, 20% were CD30+, 60% CD23+, 80% MAL+, 20% CD200+, and 0% CD273/PDL2+. Whole-exome sequencing detected alterations in genes associated with both FL/DLBCL (CREBBP, KMT2C, KMT2D, ARID1A, HIST1 members, and TNFRSF14) and PMBL (JAK-STAT pathway genes, B2M, and CD58).

View Article and Find Full Text PDF
Article Synopsis
  • * Recent updates have refined the understanding of these disorders, including the recognition of a new category for EBV-positive polymorphic B cell LPD and a provisional entity for primary nodal EBV+ T or NK cell lymphoma.
  • * The classification of EBV LPDs in children has also evolved, splitting into four distinct groups, while the classification of post-transplant lymphoproliferative disorders (PTLD) remains consistent with prior classifications.
View Article and Find Full Text PDF
Article Synopsis
  • * A study involved whole-genome sequencing of 230 BL and 295 diffuse large B-cell lymphoma (DLBCL) tumors, revealing key mutated genes and new subgroups of BL with specific genetic traits.
  • * The research findings indicate significant genetic and clinical disparities between pediatric and adult BL, suggesting that identifying these subtypes could inform better approaches to diagnosis and treatment.
View Article and Find Full Text PDF

There has been a surge in COVID-19 vaccine-associated lymphadenopathy (LAD), including after the booster dose of vaccine. This can create diagnostic dilemmas in oncology patients as the relatively sudden LAD can mimic metastasis or cancer recurrence, at a risk of leading to additional but unnecessary anti-neoplastic therapy. Here we report the histopathologic features in a case of persistent LAD occurring in a patient with history of breast invasive ductal carcinoma which followed a COVID-19 vaccine booster.

View Article and Find Full Text PDF

Since the 2016 WHO update, progress has been made in understanding the biology of Burkitt lymphoma (BL) and the concept of high-grade B-cell lymphomas (HGBCL) that allows some degree of refinement. The summary presented here reviews in detail the discussions of the Clinical Advisory Committee and expands upon the newly published 2022 International Consensus Classification for lymphoid malignancies (Campo et al. Blood, 2022).

View Article and Find Full Text PDF
Article Synopsis
  • Large-scale molecular profiling and high-throughput sequencing have dramatically improved our understanding of the genomic characteristics of lymphoid neoplasms, leading to better classification and diagnosis of these diseases.
  • Despite advancements, current diagnosis primarily relies on morphological assessment and immunophenotyping, with genomic criteria applied only to a few cases.
  • The paper discusses the role of advanced molecular testing techniques in enhancing diagnosis, risk assessment, and treatment prediction, highlighting their importance for future precision medicine approaches in treating lymphoid malignancies.
View Article and Find Full Text PDF

Plasma cell neoplasm (PCN) is associated with characteristic chromosomal aberrations of diagnostic and prognostic significance. The presence of a small percentage of neoplastic cells is a drawback in the application of karyotyping and fluorescence in situ hybridization for the evaluation of bone marrow aspirate. The analysis of samples enriched for CD138 cells has improved the detection rate.

View Article and Find Full Text PDF
Article Synopsis
  • Mu heavy chain disease is a rare condition involving abnormal plasma cells and defective mu immunoglobulin heavy chains, and its biological mechanisms are not well understood.
  • A specific case was reported involving a patient with a MYD88 L265P mutation and deletion of 6q, both linked to lymphoplasmacytic lymphoma/Waldenström macroglobulinemia, identified through serum mass spectrometry.
  • The study found that lymphocytosis is rare in mu heavy chain disease and suggests that some cases resemble lymphoplasmacytic lymphoma more than chronic lymphocytic leukemia, especially due to the common MYD88 mutation in these patients.
View Article and Find Full Text PDF

Since the publication of the Revised European-American Classification of Lymphoid Neoplasms in 1994, subsequent updates of the classification of lymphoid neoplasms have been generated through iterative international efforts to achieve broad consensus among hematopathologists, geneticists, molecular scientists, and clinicians. Significant progress has recently been made in the characterization of malignancies of the immune system, with many new insights provided by genomic studies. They have led to this proposal.

View Article and Find Full Text PDF

Objectives: To overcome the challenges associated with molecular and cytogenetic (MG) education in hematopathology (HP), a monthly joint HP/MG conference with specific curricular goals was established and evaluated by the participants.

Methods: All cases from the HP/MG conference over 56 months were reviewed. To assess the educational impact, a survey was distributed to current/former HP/molecular genetic pathology fellows and faculty.

View Article and Find Full Text PDF

Epstein-Barr virus (EBV)-positive extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue (MALT lymphomas) were initially described in solid organ transplant recipients, and, more recently, in other immunodeficiency settings. The overall prevalence of EBV-positive MALT lymphomas has not been established, and little is known with respect to their genomic characteristics. Eight EBV-positive MALT lymphomas were identified, including 1 case found after screening a series of 88 consecutive MALT lymphomas with EBER in situ hybridization (1%).

View Article and Find Full Text PDF

Objectives: Flow cytometry (FC) is critical for the diagnosis and monitoring of hematologic malignancies. Machine learning (ML) methods rapidly classify multidimensional data and should dramatically improve the efficiency of FC data analysis. We aimed to build a model to classify acute leukemias, including acute promyelocytic leukemia (APL), and distinguish them from nonneoplastic cytopenias.

View Article and Find Full Text PDF